Antimicrobial resistance among Campylobacter strains, United States, 1997-2001

被引：209

作者：

Gupta, A

Nelson, JM

Barrett, TJ

Tauxe, RV

Rossiter, SP

Friedman, CR

Joyce, KW

Smith, KE

Jones, TF

Hawkins, MA

Shiferaw, B

Beebe, JL

Vugia, DJ

Rabatsky-Ehr, T

Benson, JA

Root, TP

Angulo, FJ

机构：

[1] Ctr Dis Control & Prevent, Atlanta, GA USA

[2] Minnesota Dept Hlth, Minneapolis, MN USA

[3] Tennessee Dept Hlth, Nashville, TN USA

[4] Maryland Dept Hlth & Mental Hyg, Baltimore, MD USA

[5] Oregon Dept Huma Serv, Portland, OR USA

[6] Colorado Dept Publ Hlth & Environm, Denver, CO USA

[7] Calif Dept Hlth Serv, Berkeley, CA USA

[8] Connecticut Dept Publ Hlth, Hartford, CT USA

[9] Georgia Dept Human Serv, Atlanta, GA USA

[10] New York State Dept Hlth, Albany, NY USA

来源：

EMERGING INFECTIOUS DISEASES | 2004年 / 10卷 / 06期

关键词：

D O I：

10.3201/eid1006.030635

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

We summarize antimicrobial resistance surveillance data in human and chicken isolates of Campylobacter. Isolates were from a sentinel county study from 1989 through 1990 and from nine state health departments participating in National Antimicrobial Resistance Monitoring System for enteric bacteria (NARMS) from 1997 through 2001. None of the 297 C. jejuni or C. coli isolates tested from 1989 through 1990 was ciprofloxacin-resistant. From 1997 through 2001, a total of 1,553 human Campylobacter isolates were characterized: 1,471 (95%) were C. jejuni, 63 (4%) were C. coli, and 19 (1%) were other Campylobacter species. The prevalence of ciprofloxacin-resistant Campylobacter was 13% (28 of 217) in 1997 and 19% (75 of 384) in 2001; erythromycin resistance was 2% (4 of 217) in 1997 and 2% (8 of 384) in 2001. Ciprofloxacin-resistant Campylobacter was isolated from 10% of 180 chicken products purchased from grocery stores in three states in 1999. Ciprofloxacin resistance has emerged among Campylobacter since 1990 and has increased in prevalence since 1997.

引用

页码：1102 / 1109

页数：8

共 43 条

[11] Empirical treatment of severe acute community-acquired gastroenteritis with ciprofloxacin [J].